These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases. D'souza MM, Sharma R, Mondal A, Jaimini A, Tripathi M, Saw SK, Singh D, Mishra A, Tripathi RP. Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427 [Abstract] [Full Text] [Related]
6. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT. Suenaga Y, Kitajima K, Ishihara T, Sasaki R, Otsuki N, Nibu K, Minamikawa T, Kiyota N, Sugimura K. Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656 [Abstract] [Full Text] [Related]
7. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence. Deleau C, Buecher B, Rousseau C, Kraeber-Bodéré F, Flamant M, des Varannes SB, Frampas E, Galmiche JP, Matysiak-Budnik T. Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319 [Abstract] [Full Text] [Related]
11. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients. Jiménez Londoño GA, García Vicente AM, Sánchez Pérez V, Jiménez Aragón F, León Martin A, Cano Cano JM, Domínguez Ferreras E, Gómez López OV, Espinosa Arranz J, Soriano Castrejón ÁM. Eur J Radiol; 2014 Dec; 83(12):2224-2230. PubMed ID: 25306106 [Abstract] [Full Text] [Related]
12. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399 [Abstract] [Full Text] [Related]
15. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. Badiee S, Franc BL, Webb EM, Chu B, Hawkins RA, Coakley F, Singer L. AJR Am J Roentgenol; 2008 Nov; 191(5):1436-9. PubMed ID: 18941082 [Abstract] [Full Text] [Related]
17. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin. Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B. J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438 [Abstract] [Full Text] [Related]
18. 18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases. Surasi DS, O'Malley JP, Bhambhvani P. J Nucl Med Technol; 2015 Sep; 43(3):229-30. PubMed ID: 25655342 [Abstract] [Full Text] [Related]
19. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, Wettergren A, Rasmussen A, Hillingsoe J, Kirkegaard P, Thomsen C. Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514 [Abstract] [Full Text] [Related]